CAJ | 학술논문

目的探讨AR在不同ER、PR状态乳腺癌中的表达及意义.方法采用免疫组化方法检测AR、ER、PR在173例乳腺癌中的表达,依据结果分组:(1)AR状态分组:AR阳性组和AR阴性组;(2)ER、PR状态分组:En组(ER、PR均阴性)、Ep组[ER和(或)PR阳性];(3)AR、ER、PR联合分组:En-AR~+(En组且AR阳性)、En-AR~-(En组且AR阴性)、Ep-AR~+(Ep组且AR阳性)、Ep-AR~-(Ep组且AR阴性),其中En-AR~-又称为均阴性组,其他三组统称为部分或完全阳性组.不同分组方法比较与临床病理特征的关系.结果 Ep组AR阳性率62.8%(54/86),En组AR阳性率37.9%(33/87),两组差异有显著性(P=0.001),AR阳性组体积小、核分裂少、组织学分级低(P<0.05);En-AR~-组表现为核分裂多、组织学分级高(P<0.01),此外En组内AR阳性者核分裂少、组织学分级低(P<0.05),Ep组内AR阳性者临床分期高(P=0.000),En-AR~+、Ep-AR~+、Ep-AR~-比较均无差异.结论 AR在不同激素状态乳腺癌中表达的意义不同,ER、PR均阴性乳腺癌表达AR者预后较好,ER、PR阳性乳腺癌表达AR者临床分期高.在选择针对性药物时应考虑到不同激素受体状态的组合.
목적 탐토AR재불동ER、PR상태유선암중적표체급의의.방법 채용면역조화방법검측AR、ER、PR재173례유선암중적표체,의거결과분조:(1)AR상태분조:AR양성조화AR음성조;(2)ER、PR상태분조:En조(ER、PR균음성)、Ep조[ER화(혹)PR양성];(3)AR、ER、PR연합분조:En-AR~+(En조차AR양성)、En-AR~-(En조차AR음성)、Ep-AR~+(Ep조차AR양성)、Ep-AR~-(Ep조차AR음성),기중En-AR~-우칭위균음성조,기타삼조통칭위부분혹완전양성조.불동분조방법비교여림상병리특정적관계.결과 Ep조AR양성솔62.8%(54/86),En조AR양성솔37.9%(33/87),량조차이유현저성(P=0.001),AR양성조체적소、핵분렬소、조직학분급저(P<0.05);En-AR~-조표현위핵분렬다、조직학분급고(P<0.01),차외En조내AR양성자핵분렬소、조직학분급저(P<0.05),Ep조내AR양성자림상분기고(P=0.000),En-AR~+、Ep-AR~+、Ep-AR~-비교균무차이.결론 AR재불동격소상태유선암중표체적의의불동,ER、PR균음성유선암표체AR자예후교호,ER、PR양성유선암표체AR자림상분기고.재선택침대성약물시응고필도불동격소수체상태적조합.
Purpose To investigate the expression and significance of androgen receptor (AR) in breast carcinoma with different ER and PR status.Methods Immunohistochemical method was used to detect AR, ER and PR expression in 173 cases of breast carcinoma, and all the cases were grouped according to: (1) AR status: AR~- positive subgroup and AR~- negative subgroup, (2) ER status: En subgroup (negative for both ER and PR), Ep subgroup (positive for ER and/or PR), (3)AR, ER and PR status: En-AR~+ subgroup (AR~- positive cases of En subgroup), En-AR~- subgroup (AR~-negative cases of En subgroup), Ep-AR~+ subgroup (AR~- positive cases of Ep subgroup), and Ep-AR~- subgroup (AR~-negative cases of Ep subgroup).En-AR~- subgroup also was called negativE-for-all subgroup, and the rest three subgroups were called partly-or-completely positive subgroup (positive for at least one of the three markers), and then, the groups were compared with clinicopathological features.Results The positive rate of AR was 62.8% (54/86) in Ep subgroup and 37.9%(33/87) in En subgroup, and there was significant difference between them (P=0.001).Compared to AR~-negative subgroup, AR~-positive subgroup had smaller tumor size, less mitosis count and lower grade(P<0.05).Compared to the other three subgroups, En-AR~- subgroup had more mitosis count and higher grade (P<0.01).In En subgroup,AR~- positive cases had less mitosis count and lower grade (P<0.05), and in Ep subgroup,AR~- positive cases had higher stage(P=0.000), but no significant difference were found among partly or completely positive subgroups.Conclusions The expression of AR may play a different role in breast carcinoma with different ER and PR status, because it indicates good prognosis in negative for both ER and PR subgroup, but bad in ER and/or PR positive subgroup. When choosing a personalized therapy, all the combinations of hormone receptor status should be considered for the patients.